Panobacumab
Panobacumab is a monoclonal antibody that has been developed for the treatment of infections caused by Pseudomonas aeruginosa, a common Gram-negative bacterium that can cause disease in plants, animals, and humans. This bacterium is known for its resistance to antibiotics, making infections difficult to treat.
Mechanism of Action[edit | edit source]
Panobacumab is a fully human monoclonal antibody that targets the lipopolysaccharide (LPS) O-polysaccharide of the serotype O11 of Pseudomonas aeruginosa. By binding to this specific antigen, panobacumab facilitates the opsonization and subsequent phagocytosis of the bacteria by the immune system, thereby aiding in the clearance of the infection.
Clinical Development[edit | edit source]
Panobacumab has undergone various stages of clinical trials to evaluate its safety and efficacy. These trials are essential to determine the appropriate dosage, potential side effects, and overall effectiveness in treating Pseudomonas aeruginosa infections, particularly in patients with cystic fibrosis or those who are immunocompromised.
Applications[edit | edit source]
The primary application of panobacumab is in the treatment of severe Pseudomonas aeruginosa infections, especially in cases where the bacteria are resistant to multiple antibiotics. This includes infections in the respiratory tract, urinary tract, and bloodstream.
Challenges and Considerations[edit | edit source]
One of the significant challenges in the development and use of panobacumab is the potential for the development of resistance. Continuous monitoring and research are necessary to ensure its long-term efficacy. Additionally, the cost of monoclonal antibody treatments can be high, which may limit accessibility for some patients.
Future Directions[edit | edit source]
Research is ongoing to explore the broader applications of panobacumab and to develop similar monoclonal antibodies targeting other serotypes of Pseudomonas aeruginosa and other resistant bacteria. The goal is to expand the arsenal of treatments available for combating antibiotic-resistant infections.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
